Dexfenfluramine

Drug Profile

Dexfenfluramine

Alternative Names: Adifax; D-fenfluramine; Dextrofenfluramine; Dipondal; IP 001; Isomeride; Obedial; Redux; S 5614

Latest Information Update: 27 Apr 2000

Price : $50

At a glance

  • Originator Servier
  • Class Anorectics; Small molecules
  • Mechanism of Action Serotonin release stimulants; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Market Withdrawal Obesity

Most Recent Events

  • 27 Apr 2000 Fenfluramine/dexfenfluramine has been withdrawn in Europe
  • 28 Sep 1998 Results of 3 studies looking at the evidence linking anorectics with valvular heart disease have been added to the Adverse Events section ,,,
  • 05 Jun 1998 A clinical study involving 1212 patients in which there appeared to be no increase in the prevalence of valvular abnormalities has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top